A Phase II, Open-Label, Multi-Center Study to Evaluate the Efficacy of 90Y-SMT 487 Administered Intravenously to Patients With Refractory Small Cell Lung or Advanced Metastatic Breast Cancer Expressing Somatostatin Receptors as Determined by OctreoScan Scintigraphy
Latest Information Update: 03 Nov 2021
At a glance
- Drugs Edotreotide Y-90 (Primary)
- Indications Breast cancer; Small cell lung cancer
- Focus Therapeutic Use
- 10 Sep 2005 New trial record.